Digestive Disease Interventions
DOI: 10.1055/s-0045-1807743
Review Article

Endoscopic Evaluation and Therapy of Intraductal Papillary Mucinous Neoplasms

Nikhil Bush
1   Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama
,
Shreyas Krishna
2   Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, Ohio
,
Ahmed Abdelbaki
2   Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, Ohio
,
Eileen S. Carpenter
3   Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan
,
3   Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan
› Institutsangaben

Abstract

As the understanding of intraductal papillary mucinous neoplasms (IPMNs) continues to evolve, so too do the diagnostic and therapeutic strategies surrounding its management. This review article aims to provide a comprehensive overview of the endoscopic evaluation and therapeutic interventions available for patients with IPMNs. Endoscopic ultrasound (EUS) plays a pivotal role in the diagnosis and risk stratification of IPMNs. Furthermore, advancements in EUS techniques, such as needle-based confocal laser endomicroscopy, contrast-enhanced EUS, and through-the-needle biopsies, provide additional diagnostic precision in the evaluation of IPMNs. The role of therapeutic interventions for IPMNs has emerged over the past decade and includes chemoablation and radiofrequency ablation, which offer minimally invasive alternatives to surgery in select cases. With this progress in endoscopic techniques, endoscopists are better equipped than ever to diagnose, risk-stratify, and treat patients with IPMNs.

Disclosures and Conflicts of Interest

J.D.M. is funded by an ACG Junior Faculty Career Development Award and Robert A. Winn Excellence in Clinical Trials Career Development Award. He has also served on the advisory board of Amgen LCM and as a speaker for Maunea Kea Technologies, Paris, France.




Publikationsverlauf

Eingereicht: 10. August 2024

Angenommen: 21. März 2025

Artikel online veröffentlicht:
15. April 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Vilela A, Quingalahua E, Vargas A. et al. Global prevalence of pancreatic cystic lesions in the general population on magnetic resonance imaging: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2024; 22 (09) 1798-1809.e6
  • 2 Tanaka S, Tsujimae M, Masuda A. et al. Metabolic syndrome accelerates the age-related increase of intraductal papillary mucinous neoplasm of the pancreas. Pancreas 2024; 53 (01) e9-e15
  • 3 Munigala S, Gelrud A, Agarwal B. Risk of pancreatic cancer in patients with pancreatic cyst. Gastrointest Endosc 2016; 84 (01) 81-86
  • 4 Roldán J, Harrison JM, Qadan M. et al. “Evolving trends in pancreatic cystic tumors: a 3-decade single-center experience with 1290 resections”. Ann Surg 2023; 277 (03) 491-497
  • 5 Quingalahua E, Al-Hawary MM, Machicado JD. The role of magnetic resonance imaging (MRI) in the diagnosis of pancreatic cystic lesions (PCLs). Diagnostics (Basel) 2023; 13 (04) 585
  • 6 Ohtsuka T, Fernandez-Del Castillo C, Furukawa T. et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology 2024; 24 (02) 255-270
  • 7 Ohno E, Balduzzi A, Hijioka S. et al. Association of high-risk stigmata and worrisome features with advanced neoplasia in intraductal papillary mucinous neoplasms (IPMN): a systematic review. Pancreatology 2024; 24 (01) 48-61
  • 8 Baba T, Yamaguchi T, Ishihara T. et al. Distinguishing benign from malignant intraductal papillary mucinous tumors of the pancreas by imaging techniques. Pancreas 2004; 29 (03) 212-217
  • 9 McCarty TR, Garg R, Rustagi T. Pancreatic cyst fluid glucose in differentiating mucinous from nonmucinous pancreatic cysts: a systematic review and meta-analysis. Gastrointest Endosc 2021; 94 (04) 698-712.e6
  • 10 Pflüger MJ, Jamouss KT, Afghani E. et al. Predictive ability of pancreatic cyst fluid biomarkers: a systematic review and meta-analysis. Pancreatology 2023; 23 (07) 868-877
  • 11 Krishna SG, Hart PA, DeWitt JM. et al. EUS-guided confocal laser endomicroscopy: prediction of dysplasia in intraductal papillary mucinous neoplasms (with video). Gastrointest Endosc 2020; 91 (03) 551-563.e5
  • 12 Magahis PT, Chhoda A, Berzin TM. et al. Risk of pancreatitis after endoscopic ultrasound-guided fine-needle aspiration of pancreatic cystic lesions: a systematic review and meta-analysis. Am J Gastroenterol 2024; 119 (11) 2174-2186
  • 13 Napoleon B, Krishna SG, Marco B. et al. Confocal endomicroscopy for evaluation of pancreatic cystic lesions: a systematic review and international Delphi consensus report. Endosc Int Open 2020; 8 (11) E1566-E1581
  • 14 Machicado JD, Napoleon B, Lennon AM. et al. Accuracy and agreement of a large panel of endosonographers for endomicroscopy-guided virtual biopsy of pancreatic cystic lesions. Pancreatology 2022; 22 (07) 994-1002
  • 15 Napoleon B, Lemaistre A-I, Pujol B. et al. In vivo characterization of pancreatic cystic lesions by needle-based confocal laser endomicroscopy (nCLE): proposition of a comprehensive nCLE classification confirmed by an external retrospective evaluation. Surg Endosc 2016; 30 (06) 2603-2612
  • 16 Machicado JD, Chao W-L, Carlyn DE. et al. High performance in risk stratification of intraductal papillary mucinous neoplasms by confocal laser endomicroscopy image analysis with convolutional neural networks (with video). Gastrointest Endosc 2021; 94 (01) 78-87.e2
  • 17 Luthra A, Hart PA, Papachristou GI. et al. Cost-benefit analysis and resource implications of endoscopic ultrasound-guided confocal endomicroscopy in pancreatic cysts. Tech Innov Gastrointest Endosc 2022; 24: 35-44
  • 18 McCarty T, Rustagi T. Endoscopic ultrasound-guided through-the-needle microforceps biopsy improves diagnostic yield for pancreatic cystic lesions: a systematic review and meta-analysis. Endosc Int Open 2020; 8 (10) E1280-E1290
  • 19 Facciorusso A, Kovacevic B, Yang D. et al. Predictors of adverse events after endoscopic ultrasound-guided through-the-needle biopsy of pancreatic cysts: a recursive partitioning analysis. Endoscopy 2022; 54 (12) 1158-1168
  • 20 Singhi AD, Nikiforova MN, McGrath K. DNA testing of pancreatic cyst fluid: is it ready for prime time?. Lancet Gastroenterol Hepatol 2017; 2 (01) 63-72
  • 21 Springer S, Wang Y, Dal Molin M. et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology 2015; 149 (06) 1501-1510
  • 22 Nikiforova MN, Wald AI, Spagnolo DM. et al. A combined DNA/RNA-based next-generation sequencing platform to improve the classification of pancreatic cysts and early detection of pancreatic cancer arising from pancreatic cysts. Ann Surg 2023; 278 (04) e789-e797
  • 23 Paniccia A, Polanco PM, Boone BA. et al. Prospective, multi-institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts. Gastroenterology 2023; 164 (01) 117-133.e7
  • 24 Yamashita Y, Kawaji Y, Shimokawa T. et al. Usefulness of contrast-enhanced harmonic endoscopic ultrasonography for diagnosis of malignancy in intraductal papillary mucinous neoplasm. Diagnostics (Basel) 2022; 12 (09) 2141
  • 25 Yamashita Y, Ueda K, Itonaga M. et al. Usefulness of contrast-enhanced endoscopic sonography for discriminating mural nodules from mucous clots in intraductal papillary mucinous neoplasms: a single-center prospective study. J Ultrasound Med 2013; 32 (01) 61-68
  • 26 El Hajj II, Brauer BC, Wani S, Fukami N, Attwell AR, Shah RJ. Role of per-oral pancreatoscopy in the evaluation of suspected pancreatic duct neoplasia: a 13-year U.S. single-center experience. Gastrointest Endosc 2017; 85 (04) 737-745
  • 27 de Jong DM, Stassen PMC, Groot Koerkamp B. et al; European Cholangioscopy Study Group. The role of pancreatoscopy in the diagnostic work-up of intraductal papillary mucinous neoplasms: a systematic review and meta-analysis. Endoscopy 2023; 55 (01) 25-35
  • 28 Fong ZV, Zwart MJW, Gorris M. et al. Intraoperative pancreatoscopy during robotic pancreatoduodenectomy and robotic distal pancreatectomy for intraductal papillary mucinous neoplasm with involvement of the main pancreatic duct. Ann Surg Open 2023; 4 (02) e283
  • 29 Salvia R, Burelli A, Perri G, Marchegiani G. State-of-the-art surgical treatment of IPMNs. Langenbecks Arch Surg 2021; 406 (08) 2633-2642
  • 30 Lester C, Walsh L, Hartz KM. et al. The durability of EUS-guided chemoablation of mucinous pancreatic cysts: a long-term follow-up of the CHARM trial. Clin Gastroenterol Hepatol 2022; 20 (02) e326-e329
  • 31 Park JK, Song BJ, Ryu JK. et al. Clinical outcomes of endoscopic ultrasonography-guided pancreatic cyst ablation. Pancreas 2016; 45 (06) 889-894
  • 32 Teoh AY-B, Seo DW, Brugge W. et al. Position statement on EUS-guided ablation of pancreatic cystic neoplasms from an international expert panel. Endosc Int Open 2019; 7 (09) E1064-E1077
  • 33 DeWitt JM, Al-Haddad M, Sherman S. et al. Alterations in cyst fluid genetics following endoscopic ultrasound-guided pancreatic cyst ablation with ethanol and paclitaxel. Endoscopy 2014; 46 (06) 457-464
  • 34 Moyer MT, Heinle JW, Rhoades SE, Birkholz JH, Peng JS. Successful EUS-guided pancreatic cyst chemoablation safely allows reduction in the frequency of radiographic surveillance: long-term follow-up of randomized prospective data. Gastrointest Endosc 2024; 99 (06) 962-970
  • 35 Papaefthymiou A, Johnson GJ, Maida M. et al. Performance and safety of EUS ablation techniques for pancreatic cystic lesions: a systematic review and meta-analysis. Cancers (Basel) 2023; 15 (09) 2627
  • 36 Vargas A, Dutta P, Carpenter ES, Machicado JD. Endoscopic ultrasound-guided ablation of premalignant pancreatic cysts and pancreatic cancer. Diagnostics (Basel) 2024; 14 (05) 564
  • 37 Oh H-C, Seo DW, Song TJ. et al. Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection treats patients with pancreatic cysts. Gastroenterology 2011; 140 (01) 172-179
  • 38 Choi J-H, Seo DW, Song TJ. et al. Long-term outcomes after endoscopic ultrasound-guided ablation of pancreatic cysts. Endoscopy 2017; 49 (09) 866-873
  • 39 Moyer MT, Sharzehi S, Mathew A. et al. The safety and efficacy of an alcohol-free pancreatic cyst ablation protocol. Gastroenterology 2017; 153 (05) 1295-1303
  • 40 Alqahtani FY, Aleanizy FS, El Tahir E, Alkahtani HM, AlQuadeib BT. Paclitaxel. Profiles Drug Subst Excip Relat Methodol 2019; 44: 205-238
  • 41 Krishna SG, Ardeshna DR, Shah ZK. et al. Intracystic injection of large surface area microparticle paclitaxel for chemoablation of intraductal papillary mucinous neoplasms: insights from an expanded access protocol. Pancreatology 2024; 24 (02) 289-297
  • 42 Othman M, Patel K, Krishna SG. et al. Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts. Endosc Int Open 2022; 10 (12) E1517-E1525
  • 43 Verco S, Maulhardt H, Baltezor M. et al. Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies. Drug Deliv Transl Res 2021; 11 (05) 1806-1817
  • 44 Othman MO, Patel K, Krishna SG, Ladd AHM, Verco S, Verco J. Sa1399 intracystic injection of submicron particle paclitaxel (SPP) for the treatment of mucinous pancreatic cystic lesions resulted in reduction in cyst volume, an interim report. Gastrointest Endosc 2020; 91: AB172-AB3
  • 45 Pai M, Habib N, Senturk H. et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015; 7 (04) 52-59
  • 46 Barthet M, Giovannini M, Lesavre N. et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy 2019; 51 (09) 836-842
  • 47 Barthet M, Giovannini M, Gasmi M. et al. Long-term outcome after EUS-guided radiofrequency ablation: prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms. Endosc Int Open 2021; 9 (08) E1178-E1185
  • 48 Karimnia V, Slack FJ, Celli JP. Photodynamic therapy for pancreatic ductal adenocarcinoma. Cancers (Basel) 2021; 13 (17) 13
  • 49 Dougherty TJ, Gomer CJ, Henderson BW. et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90 (12) 889-905
  • 50 Chi H, Yan X, Tong W, Tian Q. SpyGlass guided PDT for advanced intraductal papillary mucinous neoplasm of the bile tract: a case report and literature review. Photodiagnosis Photodyn Ther 2024; 46: 104098
  • 51 Topazian M, Zhong N, Baron TH, Vege SS, Wang KK. Photodynamic therapy of intraductal papillary mucinous neoplasm. Endoscopy 2012; 44 (02) 213-215
  • 52 Rangwani S, Juakiem W, Krishna SG, El-Dika S. Role of endoscopic ultrasound in the evaluation of pancreatic cystic neoplasms: a concise review. Diagnostics (Basel) 2023; 13 (04) 705
  • 53 Oh H-C, Brugge WR. EUS-guided pancreatic cyst ablation: a critical review (with video). Gastrointest Endosc 2013; 77 (04) 526-533
  • 54 Triantopoulou C, Gourtsoyianni S, Karakaxas D, Delis S. Intraductal papillary mucinous neoplasm of the pancreas: a challenging diagnosis. Diagnostics (Basel) 2023; 13 (12) 2015
  • 55 Machado NO, Al Qadhi H, Al Wahibi K. Intraductal papillary mucinous neoplasm of pancreas. N Am J Med Sci 2015; 7 (05) 160-175